2nd NCRI AML Academy
Diagnosis and Management of Adult AML:
where are we in 2020?
8-9 October 2020
Dr Naval Daver
Dr Naval Daver is an Associate Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center. He completed his medical school from Grant Medical College and Sir J J group of Hospitals, Mumbai followed by a residency and fellowship in hematology-oncology from Baylor College of Medicine. He is a clinical investigator with a focus on molecular and immune therapies in AML and Myelofibrosis and is principal investigator on >25 ongoing institutional, national and international clinical trials in these diseases. These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune and cytotoxic agents, and identifying and overcoming mechanism of resistance. He is especially interested in developing monoclonal and bispecific antibodies, immune checkpoint and vaccine based approaches, as well as targeted and apoptotic therapies in AML and is leading a number of these trials at MDACC. Dr Daver has published >200 peer-reviewed manuscripts and is on the editorial board of numerous hematology specific journals. He has also authored numerous abstracts at national and international conferences.
Dr Ewe Platzbecker
After graduating from medical school in 1996, I first started medical training in heart surgery. Since 1998, I have been working at the Department of Haematology and Oncology at the University Hospital “Carl Gustav Carus” in Dresden, Germany. Between 2001 and 2003 I completed a 2-year postdoctoral fellowship provided by the Humboldt-foundation at the Fred Hutchinson Cancer Research Center in Seattle, USA. From 2012 to 2018 I held a position of Professor of Haematology at the University Hospital “Carl Gustav Carus” in Dresden and was the head of the section of Haematology as well as chair of the medical ethics committee of the TU Dresden. In 2015 I was appointed as Transcampus Professor of Haematology at the Faculty of Life Sciences and medicine at King’s College London. Since October 2018 I am heading the Haematology program at the University Hospital in Leipzig as Director of the Medical Clinic I, Haematology and Cell Therapy. I am a steering committee member of the SAL group, speaker of the German MDS study group, I have co-founded the European Myelodysplastic Syndromes Cooperative Group (EMSCO) in 2012 and I am chairing the MDS SWG of the EHA.
My clinical expertise lies in haematological malignancies with a focus on myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). My main scientific interest involves the translational exploration of innovative treatment options for these patients involving the use of allogeneic hematopoietic stem cell transplantation and immunological approaches.
I also have a longstanding interest on the impact of iron overload in MDS and this topic has been the focus of some works and clinical trials I have conducted (see references below). It was in this context that I first became aware of the fascinating work of Dr Vinchi, together with whom I established fruitful collaborations to better understand the detrimental action of iron excess in MDS and some related complications. Building on the existing collaboration, I will serve as consultant for the human studies of the current project focused on the role of iron as CVD risk factor in MDS.
Professor Andrew Wei
Andrew Wei, MBBS, PhD
Alfred Hospital and Monash University, Melbourne, Australia
Adjunct Associate Professor Andrew Wei is Hematologist and Medical Research Future Fund Fellow at Alfred Hospital in Melbourne, Australia, where he conducts clinical and translational acute myeloid leukemia (AML) research in collaboration with Monash University, Melbourne. He joined the Alfred Hospital in 2008 where he has led the AML program as principal investigator. He has authored > 100 publications in peer-reviewed journals and has been the AML working party chairperson for the Australasian Leukaemia and Lymphoma Group (ALLG) since 2009.